G

Monte Rosa Therapeutics
D

GLUE

12.140
USD
-0.46
(-3.65%)
Post Trading·12.280USD+0.140(+1.15%)
حجم التداول
28,708
الربح لكل سهم
-1
العائد الربحي
-
P/E
-7
حجم السوق
1,035,704,688
أصول ذات صلة المقالات
المزيد

العنوان: Monte Rosa Therapeutics

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programsin clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).